Loading...
•
Sep 30, 2024
Rocket Q3 2024 Earnings Report
Rocket Pharmaceuticals reported financial results for Q3 2024 and highlighted recent progress.
Key Takeaways
Rocket Pharmaceuticals reported cash, cash equivalents and investments of $235.7 million as of September 30, 2024. Enrollment was completed in the RP-A501 program for Danon disease and in the low dose cohort of the RP-A601 program for PKP2-ACM. Mikael Dolsten was appointed to the Board of Directors.
Enrollment completed in Phase 2 pivotal study of RP-A501 for Danon disease.
Enrollment completed in low dose cohort of Phase 1 study of RP-A601 for PKP2-ACM.
Rolling BLA submission initiated for RP-L102 for Fanconi Anemia.
Mikael Dolsten, M.D., Ph.D., appointed to Board of Directors.
Rocket
Rocket
Forward Guidance
Rocket expects its cash, cash equivalents and investments will be sufficient to fund its operations into 2026.
Positive Outlook
- Sufficient cash to fund operations into 2026.
- Producing AAV cGMP batches at the Company’s Cranbury, N.J. R&D and manufacturing facility.
- Continued development of its six clinical and/or preclinical programs.
- Advancing RP-A501 program for Danon disease.
- Advancing RP-A601 program for PKP2-ACM.